
Minimal residual disease testing appears to be a valuable tool for predicting outcomes and potential relapse in patients with lymphoid malignancies.

Your AI-Trained Oncology Knowledge Connection!

Georges Azzi, MD, is a hematologist/oncologist and co-director of the Department of Hematology/Oncology, Prostate Cancer, at Holy Cross Health, in Fort Lauderdale, Florida. Born and raised in Lebanon, he received his medical degree from Saint Joseph University of Beirut. He completed a fellowship in medical oncology with honors from the University of Miami Miller School of Medicine. Dr. Azzi has authored multiple peer-reviewed articles in hematology/oncology. He is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Association of Cancer Research (AACR), the American College of Physicians (ACP), and the Florida Society of Clinical Oncology. He is board certified in hematology and oncology.

Minimal residual disease testing appears to be a valuable tool for predicting outcomes and potential relapse in patients with lymphoid malignancies.

Measures should be taken to encourage more community oncologists to adopt minimal residual disease testing in patients with lymphoid malignancies, according to Georges Azzi, MD, of Holy Cross Health.

Published: December 21st 2023 | Updated: